




invite

INVITE Survey 2024 – Results (final)


2024-11-26

Q1: collaboration area




total replies: 92


Q2: greatest value



Q2: greatest value (sub-analysis)




Q3: main driver




- scientific findings / generation of scientific understanding for defined questions
- implementation of the findings in practical use in your own area

Q3: main driver (sub-analysis)




Q4: were the expected results achieved? **INViTE**




Q4: were the expected results achieved? **invite**

(Subanalysis – Drug Delivery)



Q4: were the expected results achieved? **invite**


(sub-analysis)



Q5: if „no“, why?

Research Area	if "no" at question (4), please add a brief explanation:
Drug Delivery / Formulation Technology	Scientific knowledge cannot be integrated into practical project work, methodology too complex . Lack of quality of PhD students and supervision from the academic side (not Invite). The colleagues from Invite and the industry partner have only limited influence on PhDs who mainly work at universities. *
	Results were not satisfactory. Project was not well chosen. / Projects do not seem to be selected in consultation with main partners.
	Conflicting interests between the different partners (Tier1/2 vs academia). While projects initially started with strong industry/practical relevance, they were often shifted towards very academic questions with only few industry/practical relevance over time. Thus, the outcome of the PhD work has only little to no industry relevance anymore and is almost similar to any other PhD student funded directly by the university.
Smart Automation	pure feedback of the results, pure chance to go in contact and could improve the solutions .
Sustainability	Not relevant
	The answer option 'partially', which I would have chosen, is missing. The results are very much dependent on the quality of the person / master's student - and here there was no good choice with 2 out of 3. *
	The challenging scientific question could only be partially addressed - also due to corona - and turned out to be much more complex than expected .*
no collaboration yet	So far we have not cooperated directly in any project
	External input coming from other Tier2 partners was often not considered in the projects. Networking opportunities were not sufficient for reaching our goals of establishing new connections there - no one was interested in our contribution or input .
	transfer of the research results into development work is not optimal and its more sporradic and by chance then by design. to me. the main goal should be to have this transfer and the value that comes out of it. in other words, the work should not end by writing the thesis or a report... and i would measure the success by the final effects/outcomes.

Q6: what would help for greater benefit? INVITE




Smart Automation: 52.8%
Other: 19.6%

Collaboration area	Comment
Drug Delivery / Formulation Technology	<p>In the case of projects, greater exchange with internal Bayer experts, obtaining more input in advance so as not to 'reinvent the wheel' and not to work past the project need *</p> <p>Divisional collaboration (exchange and implementation) - Invite as moderator/bridge *</p> <p>Dedicated knowledge support within the scope of investment projects *</p> <p>Think projects through from the end before the start with regard to the relevance of the technologies developed for application in the caretaker area / division, as well as the type and manner of technology transfer during the final phase of the work (not only afterwards), ideally jointly thought through by all three parties (caretaker, INVITE, academia). *</p> <p>upfront consultation about research projects</p> <p>To benefit more from INVITE we have to have a mindshift within our company. No need that INVITE adapts.</p> <p>more industry relevant topics that are not converted into purely academia topics</p>
Smart automation	<p>Short final report (summary of findings) *</p> <p>Support of a publication, if supported by all project parties *</p> <p>AIRA - great collaboration *</p>
Sustainability	<p>Early evaluation of potential follow-up projects or related projects *</p>
no collaboration yet	<p>spreading the word</p> <p>projects should be connected to long and long term outcomes of the business.</p> <p>Difficult to say without having cooperated with INVITE but most probably implementation support</p> <p>We are only at the beginning of a project *</p> <p>Connections to other big-pharma companies in Europe (+ Switzerland and UK).</p>

* translation from German


Q7: what prevented collaboration up to now?



Collaboration area	Comment
Drug Delivery / Formulation Technology	I am a university partner ;
	project has started;
	not clear to us how we can influence the list of projects the pharma partners can choose from;
	Restrictions on the use of proprietary substances for studies; *
Smart automation	I haven't let that stop me yet; *
	There are too many secondary tasks that keep one from actually working on the project; *
	lack of available capacity; *
Sustainability	There have already been projects with Invite (AIRA); *
	I am a fan of the collaboration with Invite ; *
	Budget limitation in our own company; *
no collaboration yet	nothing;
	The framework conditions for working with INVITE are not always clear to everyone or have changed; *
	Ongoing projects started before knowing INVITE;
	unique selling point / fit for current needs not yet given, but constant screening thereof ;
	lacking commitment in CH;

* translation from German

Q8: overall rating



Q9: Further comments

Drug Delivery / Formulation Technology



Current [resource bottlenecks](#) reduce scope for further cooperation *

In my view, the assignment of industry representatives and additional [dialogue in a smaller expert group is very valuable](#). If necessary, more involvement and [joint publication/communication](#) could also take place here *

INVITE as a scout / intermediary / innovation manager / PMO for public funding consortia would be an attractive additional value proposition. Perhaps it would be possible to bring DDIC partners and other companies in the local area and generate a critical mass for [more public funding projects](#)? *

Proposal: increased investment in '[system maintenance](#)' - maintenance and servicing of (rental) equipment *

In my opinion, the work on a technical-scientific topic by a qualified student selected by INVITE, who is guided and supervised by a full-time [INVITE employee in a team with an caretaker from the industrial partner is a successful model](#). Thank you for your great support. * / **

Costs postdoc / PhD student INVITE Comparison with direct employment (postdoc) or direct collaboration with university (PhD student) in figures and [justify any higher costs with real higher value if via INVITE](#) *

Another advantage that INVITE offers was not even mentioned in this survey. The [premises are ideal for networking and exchanging ideas with external partners from industry and academia](#). * / **

Recognition and thanks for the great [commitment to the realisation of industry-wide standards](#), which make meaningful optimisations possible in the first place *

[Projects do not seem to be selected in consultation with main partners](#).

it is somehow unclear whether all this is about INVITE or DDIC

We appreciate different partners hosting the the face to face meetings and would highly recommend to [let all partners organize a face to face](#). We would be happy to host it in the Siemens Process Automation World in Karlsruhe as well. **

Q9: Further comments

Smart Automation



The greatest added value lies in the direct cooperation in concrete projects that are also implemented, i.e. the use of the scientific assistants and the well-trained permanent employees, ideally utilising the expertise of all three INVITE departments --- especially in the area of smart automation, I see even more [potential in the pre-competitive exploration/comparison/joint development of technologies/processes and generally the pre-competitive exchange](#). In other words, [more focus on the users of the technologies](#) (Bayer, NovoNordisk, Roche, Sanofi, GSK, Biontech, J&J, BI, Merck, Takeda ...) and not the solution providers. *

In my opinion, the work on a technical-scientific topic by a qualified student selected by INVITE, who is guided and supervised by a full-time [INVITE employee in a team with an caretaker from the industrial partner is a successful model](#). Thank you for your great support. * / **

Another advantage that INVITE offers was not even mentioned in this survey. The [premises are ideal for networking and exchanging ideas with external partners from industry and academia](#). * / **

Recognition and thanks for the great [commitment to the realisation of industry-wide standards](#), which make meaningful optimisations possible in the first place * / **

In a few of the assessment interviews I would have liked a little [more moderation](#) in order to [achieve more focussed results](#).*

Great collaboration in 2 [AIRA Challenges](#) *

Excellent [PM skills](#) in addition to scientific expertise.

We think it's great to work with Invite, but the contact people change very often.

Let's stay closer in contact / discussion / feedback. ([Digitalization - NOA, APL, MTP](#))

We appreciate different partners hosting the the face to face meetings and would highly recommend to [let all partners organize a face to face](#). We would be happy to host it in the Siemens Process Automation World in Karlsruhe as well. **

Q9: Further comments

Sustainability



Limited collab to date so can not answer many questions

Continuity is very important in the course of the project, handover of aquired knowledge must be ensured despite changing staff (students). *

The evaluation was based on three individual cases (Master's theses): one went very well with excellent results; one went badly, the other very badly.

Keep up the good work

* translation from German

Q9: Further comments

„no collaboration yet with INVITE“



The [sandbox capabilities](#) you could offer are extremely interesting

the Link to Bayer is too strong (e.g. intensive employee exchange between Invite and Bayer) -

[hard for other companies to recruit personel from invite](#) after completion of the phd students. Minds of the involved people are too rigid/ conservative.

invite.

DDiC

Drug Delivery innovation Center



INVITE GmbH
CHEMPARK • Building W32 • 51368 Leverkusen • Germany
Phone: +49 214 31 2030 • Email: info@invite-research.com
www.invite-research.com

Research Center
Otto-Bayer-Straße 32
51061 Cologne • Germany
51°01' N 6°99' E



**The bridge between
research
& industrial application.**

invite

With our engagement and drive for innovation we ...

- ... build on a network of academic and industrial partners.
- ... form win-win collaborations with everyone.
- ... combine the strengths of our diverse and interdisciplinary team.
- ... constantly challenge the status quo.
- ... enjoy realizing your break through application.